SDGR: Q3 growth and raised FY26 guidance came alongside a $37.7m net loss

What happened

Schrödinger reported third-quarter revenue of $64.5 million, up 19% year over year, and annual contract value (ACV), a measure of contracted business, grew 17%. It raised ACV and drug discovery guidance for the fiscal year, while its net loss widened to $37.7 million and hosted software revenue grew 49%.

Confirmed

Global impact / market context

Higher revenue, hosted software growth, and raised guidance point to stronger demand and expected business activity, which could support future revenue. However, the wider $37.7 million loss shows the company is not yet translating that growth into improved profitability, a key trade-off for investors.

Analyst inference

For investors, this report presents a mixed operating picture: subscription-related measures and hosted software revenue grew, and management raised two guidance measures, but the net loss widened. The supplied information gives no share-price response, cash position, or explanation for the larger loss.

Analyst inference

What to watch

1. Compare future revenue and ACV growth, a measure of contracted business, with the raised guidance to assess whether demand supports the higher outlook. Analyst inference
2. Watch whether hosted software revenue growth continues; stronger sales could increase revenue, though the reported figures do not establish its effect on profit. Analyst inference
3. Look for the reasons the net loss widened and whether losses affect cash available to fund operations and drug discovery work. Analyst inference

Evidence

• Original source link unavailable